Literature DB >> 26883763

Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report.

G Vancieri1, A Bellia1, D Lauro2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26883763     DOI： 10.1007/s40618-016-0439-3

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  3 in total

Review 1.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

Authors:  Mabel Ryder; Margaret Callahan; Michael A Postow; Jedd Wolchok; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2014-03-07       Impact factor: 5.678

Review 2.  Ipilimumab-induced hypophysitis: review of the literature.

Authors:  P B Araujo; M C A Coelho; M Arruda; M R Gadelha; L V Neto
Journal:  J Endocrinol Invest       Date:  2015-05-10       Impact factor: 4.256

3.  Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.

Authors:  Shintaro Iwama; Alessandra De Remigis; Margaret K Callahan; Susan F Slovin; Jedd D Wolchok; Patrizio Caturegli
Journal:  Sci Transl Med       Date:  2014-04-02       Impact factor: 17.956
  3 in total
  2 in total

Review 1.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22

2.  Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.

Authors:  Kai Cui; Ziqi Wang; Qianqian Zhang; Xiaoju Zhang
Journal:  Ann Transl Med       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.